Gifoni Ana Carolina Leite Vieira Costa, Gifoni Markus Andret Cavalcante, Wotroba Camila Martins, Palmero Edenir Inez, Costa Eduardo Leite Vieira, Dos Santos Wellington, Achatz Maria Isabel
D'Or Institute for Research and Education (IDOR) and Rede D'Or São Carlos Hospital, Fortaleza, Brazil.
Surgery Department - Federal University of Ceara, Fortaleza, Brazil.
Front Oncol. 2022 Jul 22;12:932957. doi: 10.3389/fonc.2022.932957. eCollection 2022.
There is a significant lack of epidemiological data on hereditary cancer in Northeast Brazil. This is the largest study on the prevalence and mutational spectrum of cancer predisposition genes conducted in this region and the first in the State of Ceará.
Patients ≥18 years of age that were referred to CHANCE (Grupo de Câncer Hereditário do Ceará) from March 2014 to December 2020 with testing criteria for breast cancer susceptibility genes according to NCCN v.1.2021 were eligible to participate. The inclusion of patients was limited to one individual per family and to those born in the State of Ceará. All patients underwent a hereditary cancer panel testing with at least 30 genes.
A total of 355 patients were included, and 97 (27.3%) carried a P/LP germline variant in 18 different genes. Among the 97 P/LP carriers, (31, 31.9%) and (25, 25.7%) were the most frequently mutated genes, followed by (10, 10.3%), (7, 7.2%) and (4, 4.1%). A small number of recurrent variants (detected in three or more individuals) in , , and represented the majority of the P/LP variants described in this cohort.
In this cohort, the prevalence of L/PL was high, particularly involving the , , , and genes and, to a lesser extent than expected, the gene. A high frequency of recurrent variants was also observed, for which further and larger analyses should clarify the presence of any possible founder effect. Characterizing the mutational profile of cancer predisposition genes in diverse populations may contribute to cancer prevention and therapeutic management.
巴西东北部关于遗传性癌症的流行病学数据严重匮乏。这是该地区开展的关于癌症易感基因患病率和突变谱的最大规模研究,也是塞阿拉州的首例此类研究。
2014年3月至2020年12月期间,根据美国国立综合癌症网络(NCCN)v.1.2021版乳腺癌易感基因检测标准被转诊至CHANCE(塞阿拉遗传性癌症小组)的18岁及以上患者有资格参与研究。患者纳入限于每个家庭一名个体且为出生在塞阿拉州的人。所有患者均接受了至少30个基因的遗传性癌症基因检测。
共纳入355例患者,其中97例(27.3%)在18个不同基因中携带可能致病/致病的种系变异。在97例可能致病/致病变异携带者中,[基因名称1](31例,31.9%)和[基因名称2](25例,25.7%)是最常发生突变的基因,其次是[基因名称3](10例,10.3%)、[基因名称4](7例,7.2%)和[基因名称5](4例,4.1%)。[基因名称6]、[基因名称7]、[基因名称8]和[基因名称9]中的少数复发性变异(在三个或更多个体中检测到)占该队列中描述的可能致病/致病变异的大部分。
在该队列中,可能致病/致病变异的患病率较高,尤其涉及[基因名称1]、[基因名称2]、[基因名称3]、[基因名称4]和[基因名称5]基因,而[基因名称10]基因的涉及程度低于预期。还观察到高频复发性变异,对此进一步的大规模分析应能阐明是否存在任何可能的奠基者效应。描绘不同人群中癌症易感基因的突变谱可能有助于癌症预防和治疗管理。